Contact us

Contact

At Fresenius Kabi, we welcome your questions, comments and requests.

To report any adverse event (also known as side effects) that might be related to a Fresenius Kabi pharmaceutical product or medical device, please contact us by using below offered contact details. These requests will be processed immediately.

Company Related ​Inquiries:

Tel +44 (0)1928 533 533
Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT

Adverse E​vents:​

Adverse events must be reported.

Reporting forms and information can be found at:
yellowcard.mhra.gov.uk (for UK residents)

hpra.ie (for residents of the Republic of Ireland)

Adverse events should also be reported to Fresenius Kabi Ltd.
Phone: +44 (0)1928 533612 (please use only for reporting adverse events)
E-mail: pharmacovigilance.gb@fresenius-kabi.com
Cestrian Court, Eastgate Way, Manor Park, Runcorn, Cheshire, WA7 1NT

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ (for UK residents) or see http://www.hpra.ie/homepage/medicines/safety-information/reporting-suspected-side-effects (for residents of the Republic of Ireland). By reporting side effects, you can help provide more information on the safety of this medicine.

  • KabiCare has been developed and funded by Fresenius Kabi Ltd. IDACIO is a registered trademark of Fresenius Kabi Ltd.

020/IDACIO/PSP/FKUK-IRL April 2020 

We use cookies to ensure the correct functioning of this website, provide the best possible service to you, enhance your user experience, and optimise our website. Find out more about how we collect and use your data and how you can change your settings.

I consent > Refuse cookies >

You are leaving the KabiCare website now. Please note that Fresenius Kabi have no affiliation or control over the content available on external third-party websites.

Continue

You are now leaving the KabiCare website and will be re-directed to your local Fresenius Kabi corporate website.

For general product information about IDACIO (adalimumab) for members of the public, please refer to the Patient Information Leaflet (PIL) and the Summary of Product Characteristics(SmPC).

If you have any questions, please consult your healthcare professional team.

Continue